We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Beckman Coulter and SphingoTec Partner to Improve Kidney Health Assessment in Critical Care

By LabMedica International staff writers
Posted on 10 Oct 2024

The incidence of acute kidney injury (AKI) is rising in both hospital and community settings, with an estimated 13 million people affected globally each year. More...

Current biomarkers used in critical care to detect AKI include serum creatinine and urine output. However, these biomarkers have significant limitations, offering delayed, error-prone, and unspecific insights. Emerging research highlights that the kidney function biomarker Proenkephalin 119-159 (penKid) can address these shortcomings. PenKid, a real-time biomarker present in plasma, provides a more accurate and timely assessment of kidney function, especially in critical care environments. Unlike traditional methods, penKid has been shown to detect kidney function decline earlier and is not influenced by inflammation, which may allow for earlier interventions and better patient outcomes. Now, a new partnership aims to improve kidney health assessment in critical care by leveraging the penKid kidney function biomarker.

In an effort to enhance kidney health assessments in critical care, Beckman Coulter Diagnostics (Brea, CA, USA) has partnered with SphingoTec GmbH (Hennigsdorf, Germany) to integrate SphingoTec's penKid assay into Beckman Coulter's extensive test offerings on its Access Family of immunoassay analyzers. This collaboration marks the first central laboratory license for a penKid assay and seeks to significantly expand diagnostic capabilities for AKI worldwide by leveraging Beckman Coulter's large installed base of instruments. Under this agreement, Beckman Coulter will develop and validate a fully automated diagnostic test for penKid using SphingoTec's IVD-certified assay, which has already been implemented as a routine test in select university hospitals. This partnership will make penKid assays widely available in central laboratories, enabling critical care physicians to perform timely and accurate kidney health assessments.

“Acute kidney injury exerts a profound impact on patients globally, complicates acute and chronic illnesses frequently resulting in poor outcomes, and rivals many other critical diseases in its severity and consequences,” said Kevin O’Reilly, President, at Beckman Coulter Diagnostics. “The published evidence for penKid testing combined with SphingoTec’s scientific expertise provides an exciting opportunity to improve kidney health management. Working with SphingoTec, our goal is to expand access to and improve workflow from this important kidney health innovation underscoring our commitment to enhancing patient care worldwide.”

“The development of a penKid-based assay for use on Beckman Coulter’s globally installed immunoassay platforms represents a significant step toward realizing our vision of transforming diagnostic innovation into tangible patient benefits,” added Deborah Bergmann, Managing Director and CEO of SphingoTec. “This partnership accelerates our mission to deliver precise, actionable insights to clinicians worldwide, ultimately improving outcomes for patients suffering from acute kidney injury.”

Related Links:
Beckman Coulter Diagnostics
SphingoTec GmbH 


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TRAcP 5b Assay
TRAcP 5b (BoneTRAP) Assay
New
Hemoglobin/Haptoglobin Assay
IDK Hemoglobin/Haptoglobin Complex ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Pathology

view channel
Image: AI-analyzed images from the FDM microscope show platelet clumps in motion (Photo courtesy of Hirose et al CC-BY-ND)

AI Microscope Spots Deadly Blood Clots Before They Strike

Platelets are small blood cells that act as emergency responders in the body, rushing to areas of injury to help stop bleeding by forming clots. However, sometimes platelets can overreact, leading to complications.... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.